Breast Cancer Clinical Trial
— MMHTROfficial title:
Feasibility of a Modular mHealth for Tailored Rehabilitation During the Treatment of Breast Cancer
| Verified date | October 2022 |
| Source | Samsung Medical Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study investigated the feasibility of the novel modular mobile health (mHealth) for personalized rehabilitation and explored the participants' satisfaction and app data during treatment of breast cancer.
| Status | Completed |
| Enrollment | 44 |
| Est. completion date | March 30, 2021 |
| Est. primary completion date | March 30, 2021 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 20 Years to 70 Years |
| Eligibility | Inclusion Criteria: - Unilateral breast cancer at TNM stage 0 ~ III - Patients who will undergo the treatment (chemotherapy, radiation therapy, and hormone therapy) after surgery - Patients who had a mobile phone (Android or iOS) Exclusion Criteria: - Patients who have metastases or recurrence to other organs were excluded |
| Country | Name | City | State |
|---|---|---|---|
| Korea, Republic of | Samsung Medical Center | Seoul | Gangnam-gu |
| Lead Sponsor | Collaborator |
|---|---|
| Samsung Medical Center |
Korea, Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | satisfaction score in app contents | satisfaction score in app contents, Likert scale (5-point, higher scores mean a better) | 1 to 12month | |
| Primary | Needs score in app contents | Needs score in app contents, Likert scale (5-point, higher scores mean a better) | 1 to 12month | |
| Primary | DASH (Disabilities of Arm, Shoulder, Hands) | Change from Baseline DASH score at 12 months, higher scores mean a worse (0-100) | 1 month, 2month, 4month, 6month, 9month, 12month | |
| Secondary | Physical measurement (handgrip strength) | Handgrip strength (kg) | 1 to 12month | |
| Secondary | Physical measurement (of body composition, BMI) | Body mass index | 1 to 12month | |
| Secondary | Physical measurement (of body composition, muscle mass) | muscle mass | 1 to 12month | |
| Secondary | Physical measurement (upper extremity volume) | differences in arm circumference | 1 to 12month | |
| Secondary | Physical activity (IPAQ-SF Questionnaire) | Total METs within recent 7 days (vigorous, moderate, walking, sitting), higher values mean a better | 1 to 12month | |
| Secondary | PRO-CTCAE (patients reported outcomes) | Symptoms during treatment | 1 to 12month | |
| Secondary | Distress thermometer (distress level) | Distress level during treatment, higher scores mean a worse (0-10) | 1 to 12month | |
| Secondary | App use data (personal health record)_Exercise compliance rate | Exercise time, higher values mean a better | 1 to 12month | |
| Secondary | App use data (personal health record)_Physical activity change | daily step count (number), higher values mean a better physical activity | 1 to 12month | |
| Secondary | App use data (personal health record)_interest of contents | contents view (number), higher values mean a better compliance rate | 1 to 12month | |
| Secondary | App use data (personal health record)_sleep | sleep compliance rate (%), higher values mean a better compliance rate | 1 to 12month |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |